Evaluating the Effectiveness of Intramuscular Versus Intravenous Tranexamic Acid for Minimizing Blood Loss After Total Hip Arthroplasty: A Randomized Controlled Trial

Conditions: Blood Loss After a Total Hip Replacement

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: Yes

Phase: EARLY_PHASE1

Enrollment: 128

Sponsor: Alexandria University

Location: Alexandria university main hospitals Alexandria

Summary

Intramuscular vs. Intravenous Tranexamic Acid for Total Hip Arthroplasty

Eligibility Criteria

Inclusion Criteria: 1. Adult patients aged 18 years and older. 2. Scheduled to undergo elective primary total hip arthroplasty. 3. Able to provide informed consent. Exclusion Criteria: * 1\. History of renal failure or kidney transplant. 2. History of an arterial thromboembolic event (such as myocardial infarction or stroke) within the past year. 3\. Placement of an arterial stent within the past year. 4. History of deep venous thrombosis (DVT) or pulmonary embolism (PE). 5. Known contraindications to tranexamic acid. 6. Pregnancy or breastfeeding. 7. Refusal to participate or refusal to consent to receive blood products.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07817537). StuddyBuddy aggregates publicly available trial information.